Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
CG Oncology Inc.

CG Oncology Inc. (CGON) Stock Overview

Explore CG Oncology Inc.’s financial performance, market position, analyst ratings, and future outlook.

CGON●NASDAQ
HealthcareBiotechnology
$67.38
$0.97(1.42%)
U.S. Market opens in 0h 23m

CG Oncology Inc. (CGON)

Meyka AI Score

Z

Key Financials

Market Cap5.9B
P/E Ratio-24.86
EPS (TTM)$-2.69
ROE-0.25%
Fundamental Analysis

AI Price Forecasts

1 Month$71.31
3 Months$86.83
1 Year Target$86.90

CGON Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of CG Oncology Inc. (NASDAQ: CGON) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, CG Oncology Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CGON on the NASDAQ shows an RSI of 38.45, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $86.90 for the NASDAQ listing.

Key metrics behind CG Oncology Inc.'s NASDAQ-traded stock include a P/E ratio of -24.86 and a market capitalization of 5.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CGON on the NASDAQ.

Price Performance (NASDAQ: CGON)

1-Day Change
-1.42%
5-Day Change
-2.80%
1-Month Change
-9.67%
3-Month Change
-4.24%
6-Month Change
-0.15%
Year-to-Date (YTD) Change
62.28%
1-Year Change
69.08%
3-Year Change
81.28%
5-Year Change
81.28%
All-Time (Max) Change
81.28%

Contact Information

https://cgoncology.com
+1 949 354 1630
3000 Pegasus Park Drive, Dallas, TX, 75247

Company Facts

1,420 Employees
IPO DateJan 25, 2024
CountryUS
Actively Trading

Frequently Asked Questions